TORONTO, Ontario — February 13, 2026 — Leads & Copy —
Conavi Medical Corp. highlighted the publication of new peer-reviewed research in Cardiovascular Research by the European Society of Cardiology. The research, titled “Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head-to-head comparison against histology,” focuses on hybrid intravascular imaging technologies.
The study analyzed IVUS-OCT images and matched histological sections from 10 cadaveric human hearts. The results showed that a histology-trained hybrid IVUS-OCT deep-learning classifier outperformed single-modality IVUS, single-modality OCT, and expert readers in plaque characterization. This supports the clinical and commercial value of comprehensive hybrid imaging for enhancing treatment planning.
Dr. Brian Courtney, a pioneer in hybrid IVUS-OCT imaging and co-inventor of the foundational hybrid imaging technology that underpins Conavi’s platform, contributed to the publication. Co-authors included imaging experts in Canada, Europe, and the USA, as well as artificial intelligence researchers at Queen Mary University of London.
Tom Looby, Chief Executive Officer of Conavi Medical, stated that peer-reviewed academic research continues to reinforce the clinical value proposition behind Conavi’s technology platform. He added that as the field moves toward more precise, image-guided coronary interventions, research highlighting the complementary strengths of IVUS and OCT underscores the importance of comprehensive hybrid systems.
Conavi is advancing the development and commercialization of its next-generation hybrid IVUS-OCT imaging solutions. The company has submitted its next-generation Novasight imaging system to the U.S. Food and Drug Administration (FDA) for regulatory clearance, while continuing preparations to support commercialization and clinical adoption.
In addition, the Company announced that it has granted stock options to Mark Quick, Chief Financial Officer on February 10, 2026. As part of its long‑term incentive program, the Company granted options to purchase a total of 1,000,000 common shares at an exercise price equal to the five-day volume‑weighted average trading price (“VWAP”) of the shares on the date of grant, being $0.41 per share. The options vest in accordance with the Company’s stock option plan and expire ten years from the date of grant. The grant of these options remains subject to all necessary regulatory approvals.
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has 510(k) regulatory clearance in the U.S., Canada, China, and Japan.
For additional details, the publication can be accessed at: https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvaf281/8443065
Source: Conavi Medical
